<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797069</url>
  </required_header>
  <id_info>
    <org_study_id>BK20</org_study_id>
    <nct_id>NCT00797069</nct_id>
  </id_info>
  <brief_title>Comparison of Nutritional Products for People With Type 2 Diabetes</brief_title>
  <official_title>Comparison of Nutritional Products for People With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the glycemic and insulinemic responses of a standard nutritional product with two&#xD;
      diabetes-specific nutritional products in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.</measure>
    <time_frame>Three crossover periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.</measure>
    <time_frame>Three crossover periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>standard nutritional product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard nutritional product not specific for diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetes specific product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetes specific nutritional product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental diabetes specific product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes specific experimental nutritional product</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard nutritional product (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>standard nutritional product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional product for diabetes (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>diabetes specific product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diabetes specific experimental nutritional product (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>Experimental diabetes specific product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject states that he/she has type 2 diabetes (as evidenced by use of oral&#xD;
             hypoglycemic medication for at least two months).&#xD;
&#xD;
          2. Subject is between 18 and 75 years of age, inclusive.&#xD;
&#xD;
          3. Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum&#xD;
             prior to screening visit.&#xD;
&#xD;
          4. If female is of childbearing potential, is practicing a method of birth control.&#xD;
&#xD;
          5. Subject's BMI is &gt; 18.5 kg/m2 and &lt; 35 kg/m2.&#xD;
&#xD;
          6. If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid&#xD;
             medication or hormone therapy, subject has been on constant dosage for at least two&#xD;
             months prior to screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject uses exogenous insulin for glucose control.&#xD;
&#xD;
          2. Subject states that he/she has type 1 diabetes.&#xD;
&#xD;
          3. Subject states that he/she has a history of diabetic ketoacidosis.&#xD;
&#xD;
          4. Subject takes an alpha-glucosidase inhibitor.&#xD;
&#xD;
          5. Subject states that he/she has a current infection ; has had inpatient surgery, or&#xD;
             corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior&#xD;
             to screening visit.&#xD;
&#xD;
          6. Subject states that he/she has an active malignancy (excluding the following dermal&#xD;
             malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the&#xD;
             cervix).&#xD;
&#xD;
          7. Subject states that he/she has had a significant cardiovascular event â‰¤ six months&#xD;
             prior to screening visit; or stated history of congestive heart failure.&#xD;
&#xD;
          8. Subject states that he/she has end stage organ failure or is status post organ&#xD;
             transplant.&#xD;
&#xD;
          9. Subject states that he/she has a history of renal disease.&#xD;
&#xD;
         10. Subject states that he/she has current hepatic disease.&#xD;
&#xD;
         11. Subject states that he/she has a history of severe gastroparesis.&#xD;
&#xD;
         12. Subject states that he/she has a chronic, contagious, infectious disease, such as&#xD;
             active tuberculosis, Hepatitis B or C, or HIV.&#xD;
&#xD;
         13. Subject has taken/is currently taking any herbals, dietary supplements, or&#xD;
             medications, other than oral hypoglycemic medications, during the past four weeks&#xD;
             prior to screening visit that could profoundly affect blood glucose.&#xD;
&#xD;
         14. Subject states that he/she has clotting or bleeding disorders.&#xD;
&#xD;
         15. Subject is known to be allergic or intolerant to any ingredient found in the study&#xD;
             products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Williams, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 23, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>July 29, 2010</last_update_submitted>
  <last_update_submitted_qc>July 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bobbie Swearengin, Director Clinical Research</name_title>
    <organization>Abbott Nutrition</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

